Pharma Companies Set to Raise $5 Billion in Hong Kong IPOs in 2019
This article is for subscribers only.
Venus Medtech (Hangzhou) Inc.’s shares have been selling like hot cakes, as Hong Kong investors vie for a piece of new health-care stocks.
The Chinese maker of cardiovascular devices attracted retail orders worth more than $10 billion for its IPO, the largest among health-care listings in the city this year, according to data compiled by Bloomberg. Excessive demand drove the initial retail portion of the $331 million sale to be about 312 times subscribed, Venus said in a Monday filing.